Provigil Cost in District of Columbia 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Provigil Actually Cost in DC in 2026?

Brand Provigil from Cephalon carries a wholesale acquisition cost near $850 per month, but the overwhelming majority of patients never pay that figure. Generic modafinil 200 mg (30 tablets) averages approximately $80 per month at DC-area retail pharmacies when paid out of pocket, and manufacturer or third-party discount cards can drop that further. The gap between list price and street-level cash price for modafinil is one of the widest of any Schedule IV medication on the US market.

Modafinil was first approved by the FDA in 1998 for narcolepsy based on the US Modafinil in Narcolepsy Multicenter Study Group trial, which demonstrated that modafinil 200 mg and 400 mg significantly reduced the Epworth Sleepiness Scale score versus placebo (P<0.001) in 271 patients over nine weeks [1]. Generic modafinil entered the US market following patent expiration and now accounts for the vast majority of prescriptions written in DC and nationwide.

The FDA prescribing label for Provigil lists the approved doses as 200 mg once daily for narcolepsy and obstructive sleep apnea, and 200 mg taken approximately one hour before the start of a work shift for shift-work sleep disorder [2]. Off-label uses, including cognitive enhancement and fatigue management in neurological conditions, are prescribed at clinician discretion but are not covered under those FDA-approved indications.

Because modafinil is a Schedule IV controlled substance under the Controlled Substances Act [3], DC prescribers must hold a current DEA registration, and DC pharmacies must store and dispense it under Schedule IV recordkeeping requirements. This does not meaningfully raise the purchase price, but it does affect which telehealth platforms can prescribe it and which compounding pharmacies will fill it.

Pricing varies by pharmacy even within a small geographic area like the District. GoodRx and similar aggregators show DC-area prices ranging from roughly $30 to $120 per month for generic modafinil 200 mg (30 tablets) depending on the specific location, coupon applied, and quantity. Patients who call ahead or use a pharmacy-specific app frequently secure prices at the lower end of that band.

DC Medicaid Coverage for Provigil: Prior Authorization Requirements

DC Medicaid (administered through DC Department of Health Care Finance and its managed care organizations) covers modafinil and brand Provigil for FDA-approved indications, but requires prior authorization (PA) before filling the prescription. Without an approved PA, the pharmacy will reject the claim and the patient pays cash.

The PA process in DC Medicaid typically requires the prescriber to document the diagnosis (narcolepsy, obstructive sleep apnea with CPAP documentation, or shift-work sleep disorder), confirm that the patient meets diagnostic criteria, and, for OSA, provide evidence that CPAP therapy has been tried or is being used concurrently [2]. Turnaround on PA approvals through DC Medicaid managed care plans varies, but most plans respond within 72 hours for non-urgent requests and within 24 hours for urgent clinical submissions.

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guidelines note that wake-promoting agents including modafinil are recommended for the treatment of excessive daytime sleepiness in narcolepsy type 1 and type 2 [4]. DC Medicaid PA criteria align closely with those AASM recommendations, meaning a well-documented narcolepsy or SWSD diagnosis should clear PA without difficulty in most cases.

Patients enrolled in DC Medicaid managed care plans, specifically AmeriHealth Caritas DC and Trusted Health Plan DC, should request the specific preferred drug list (PDL) tier for modafinil from their plan, because tier placement affects any applicable copayment even after PA approval. Generic modafinil is generally placed on a lower tier than brand Provigil, so requesting the generic almost always reduces the patient's copay to $0 to $3.

DC Medicaid does not currently cover modafinil for purely off-label indications such as general fatigue, attention, or cognitive performance in the absence of a sleep disorder diagnosis. A prescriber who submits a PA for one of those uses should expect denial at the initial review stage.

Generic Modafinil vs. Brand Provigil: Is There a Clinical Difference?

Generic modafinil is bioequivalent to brand Provigil within the FDA's standard 80 to 125 percent confidence interval for AUC and Cmax [5]. The FDA requires this equivalence before approving any generic, and the agency's bioequivalence database lists multiple approved generic modafinil manufacturers [5]. Clinically, patients who switch from brand to generic report similar efficacy in the large majority of cases.

The only documented scenario where brand-to-generic switching raises clinical concern is in narrow therapeutic index drugs. Modafinil is not classified as a narrow therapeutic index drug by the FDA [5]. A clinician who believes a specific patient has a documented pharmacokinetic response difference with the generic can note "dispense as written" on the prescription, but this is uncommon and will result in substantially higher out-of-pocket costs because most insurers will not cover the brand when a generic exists.

A 2021 analysis published in JAMA Internal Medicine found that brand-name drugs for sleep and wakefulness disorders cost patients a median of 8.9 times more than their generic equivalents when paid out of pocket, a disparity that widened further in 2022 and 2023 [6]. In the DC context, that ratio translates directly to the $850 versus $80 gap described above.

Formulation matters for one subpopulation: patients with swallowing difficulties who need a scored tablet or a liquid preparation may find generic manufacturers vary in tablet scoring. Brand Provigil 200 mg tablets are scored and can be split to achieve a 100 mg dose. Generic modafinil tablets from most manufacturers are also scored, but patients should confirm with their specific pharmacy.

Compounded Modafinil in DC: Legality and Who It Helps

Compounded modafinil is legal in the District of Columbia when prepared by a state-licensed 503A pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act and dispensed pursuant to a valid patient-specific prescription [7]. DC follows federal 503A standards enforced jointly by the FDA and the DC Board of Pharmacy.

A 503A pharmacy compounds for individual patients based on a prescriber's order. It cannot manufacture bulk quantities or distribute without a prescription. The compound may use the same active pharmaceutical ingredient as commercial modafinil, but it is not required to meet the same pre-market FDA approval standards as the branded or generic product [7]. This means quality and potency can vary between compounding pharmacies, and patients should confirm that their compounding pharmacy holds current DC licensure and preferably voluntary PCAB (Pharmacy Compounding Accreditation Board) accreditation.

Why would a patient choose compounded modafinil? Three situations arise most commonly. First, a patient who needs a dose not commercially available (such as 50 mg for titration). Second, a patient with a documented allergy to an inactive ingredient in commercial tablets. Third, cost. When a prescriber has a relationship with an accredited 503A pharmacy that offers competitive pricing, the out-of-pocket cost for compounded modafinil may fall below the generic retail price.

Modafinil is a Schedule IV controlled substance, and 503A pharmacies that compound it must hold a DEA registration that covers Schedule IV substances [3]. Not all compounding pharmacies carry this registration. Patients and prescribers should verify DEA Schedule IV authorization before sending a compound order.

Telehealth Prescribing of Modafinil in DC: What the Law Allows

DC law permits telehealth prescribing of modafinil for established patient-prescriber relationships. The prescriber must hold a DC license (or a compact license recognized in DC), conduct a clinically appropriate evaluation, and document a legitimate medical purpose consistent with Schedule IV prescribing requirements [3].

Since the DEA's 2023 proposed rules on telehealth prescribing of controlled substances, there has been regulatory uncertainty at the federal level. The DEA proposed requiring an in-person evaluation before any controlled substance could be prescribed via telehealth for a new patient [8]. As of 2025, the DEA has extended temporary COVID-era flexibilities while the final rule is finalized, meaning telehealth-only prescribing of Schedule IV drugs like modafinil remains permitted for new patients under the extended telemedicine rules [8]. Patients should confirm with their specific telehealth platform that the prescriber is complying with current DEA guidance, as violations could affect prescription validity.

For narcolepsy and shift-work sleep disorder diagnoses, a thorough asynchronous or synchronous telehealth visit should include review of sleep study results (polysomnography or actigraphy), Epworth Sleepiness Scale score, medication history, and any cardiovascular contraindications. The FDA prescribing label notes that modafinil is not indicated as a replacement for sleep and that the underlying cause of sleepiness should be assessed [2].

A DC-licensed telehealth prescriber who diagnoses narcolepsy de novo should ideally coordinate with a sleep medicine specialist or order objective sleep testing before initiating modafinil, both for clinical quality and to satisfy DC Medicaid PA documentation requirements if the patient is Medicaid-enrolled.

Insurance Coverage for Provigil in DC: Employer Plans and ACA Marketplace

Most commercial insurance plans operating in DC, including CareFirst BlueCross BlueShield, Aetna, UnitedHealthcare, and Cigna, cover generic modafinil on Tier 2 or Tier 3 of their formularies. Brand Provigil is typically Tier 4 or Tier 5, or excluded entirely in favor of the generic. The patient cost-sharing under a typical DC ACA Silver plan for Tier 2 generic modafinil ranges from $10 to $45 per month after deductible.

Prior authorization is also common on commercial plans. The documentation requirements mirror DC Medicaid's: diagnosis confirmation, clinical rationale, and for OSA cases, CPAP use documentation. Narcolepsy and shift-work sleep disorder claims are the most straightforward to approve. Off-label use claims for cognitive enhancement or other non-approved indications are routinely denied across all payers.

Step therapy is an additional barrier on some commercial plans. A plan may require a trial of armodafinil (Nuvigil) or another wakefulness-promoting agent before approving modafinil, or vice versa. DC law does not prohibit step therapy for Schedule IV drugs, though DC's step therapy override law (DC Code § 31-3175 et seq.) does provide a process for clinicians to request an exception when the required step drug is medically inappropriate for a specific patient [9].

Patients appealing a step therapy denial in DC should have their prescriber document why the required alternative is contraindicated or has already failed. This documentation is the single most effective tool for overcoming a step therapy barrier at the internal appeal stage.

How to Pay the Least for Modafinil in DC: A Ranked Cost Strategy

Several paths exist to reduce the monthly cost of modafinil in DC. They are not equally accessible to every patient, and the best option depends on insurance status, diagnosis, and whether compounding is clinically appropriate.

Generic modafinil with a GoodRx or RxSaver coupon at a major DC-area pharmacy chain (CVS, Walgreens, Rite Aid, Giant Food Pharmacy) consistently prices between $30 and $55 per month for 30 tablets of 200 mg as of mid-2025. This is the fastest and most widely accessible option for uninsured patients or those whose deductibles have not been met.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) listed generic modafinil at roughly $27 per 30 tablets as of early 2025, plus a dispensing fee and shipping. DC residents can use this mail-order pharmacy with a valid prescription. This is frequently the lowest per-tablet cash price available.

DC Medicaid, for eligible patients, reduces cost to near zero for generic modafinil once PA is approved. Enrollment in DC Medicaid requires meeting income and residency criteria administered by the DC Department of Human Services.

Manufacturer patient assistance programs (PAPs) for brand Provigil exist through Teva Pharmaceuticals (which markets the brand in the US). Patients with no insurance or whose insurance does not cover Provigil may apply through Teva's assistance program. Approval typically requires income documentation showing household income below 400 percent of the federal poverty level.

The 340B drug pricing program, available at qualifying DC federally qualified health centers (FQHCs) and safety net hospitals, can provide modafinil at significantly reduced cost for eligible low-income patients who receive care at those sites. DC has several 340B-covered entities, including Unity Health Care and Mary's Center.

Drug Interactions and Safety Points DC Prescribers Flag Most Often

Modafinil is a moderate inducer of CYP3A4 and a weak inhibitor of CYP2C19 [2]. These effects are clinically relevant in several common DC patient populations.

Oral contraceptives metabolized via CYP3A4 may have reduced efficacy during modafinil use and for one month after stopping. The FDA prescribing label explicitly states that alternative or additional contraceptive methods should be used during modafinil treatment [2]. This is one of the most commonly missed counseling points in telehealth visits.

Cyclosporine, a CYP3A4 substrate used in transplant patients, may have reduced blood levels during modafinil co-administration [2]. DC's tertiary care centers (MedStar Georgetown, George Washington University Hospital, Howard University Hospital) see transplant populations where this interaction is directly relevant.

Warfarin levels may increase due to CYP2C19 inhibition by modafinil [2]. Patients on warfarin starting modafinil should have their INR checked within two weeks of initiation.

A 2020 Cochrane systematic review of modafinil for cancer-related fatigue (20 RCTs, N=2,980) found that modafinil produced a small but statistically significant reduction in fatigue scores (standardized mean difference -0.29 to 95% CI -0.49 to -0.09) compared with placebo, with headache and nausea as the most common adverse effects [10]. While this was an off-label use context, the adverse event profile described reflects what DC clinicians see in clinical practice: headache in approximately 34 percent of patients, nausea in 11 percent, and insomnia in 5 percent at the 200 mg dose.

Blood pressure should be monitored in patients with pre-existing hypertension. The FDA label notes that modafinil is not recommended in patients with left ventricular hypertrophy or a history of mitral valve prolapse who have developed MVP syndrome with prior CNS stimulant use [2].

What DC Patients Should Bring to Their First Modafinil Consultation

A productive first appointment, whether in person or via telehealth, moves faster when the patient arrives with specific documentation. Sleep study results (polysomnography report for narcolepsy or OSA diagnoses) are the highest-priority document. An Epworth Sleepiness Scale self-assessment completed before the visit saves time [4]. A current medication list is necessary to screen for the CYP interactions described above.

Patients seeking DC Medicaid coverage should ask their prescriber to complete the PA form at the time of the visit rather than after, because retrospective PA submissions delay the first fill by days to weeks. Most DC Medicaid managed care plans allow electronic PA submission through CoverMyMeds or the plan's provider portal, and same-day submission is feasible when the clinical documentation is prepared in advance.

Patients who want to explore compounded modafinil should ask their prescriber whether the indication supports it and request a referral to a PCAB-accredited 503A pharmacy in the DC area. The prescriber's office should verify the pharmacy's current DC Board of Pharmacy license and DEA Schedule IV registration before transmitting the prescription [3].

Generic modafinil 200 mg, taken as a single 200 mg oral dose each morning for narcolepsy or OSA, or as a 200 mg dose one hour before shift start for shift-work sleep disorder, remains the lowest-cost evidence-supported first-line wakefulness-promoting agent available in the District of Columbia in 2026 [2].